LOUISVILLE, Ky., Aug. 13, 2013 /PRNewswire-iReach/ -- In collaboration with the James Graham Brown Cancer Center at the University of Louisville, LBIdx™ is advancing a breakthrough blood test, the Plasma Thermogram™ (pT™). Based on a simple blood draw, researchers at LBIdx™ and the Brown Cancer Center see great promise for the pT™ test as a "game-changer" allowing physicians to monitor cancer patients more closely. Monitoring is a critical part of cancer treatment and provides physicians with vital information in the fight against cancer.
LBIdx™ and the Brown Cancer Center are initiating a clinical study that will demonstrate the pT™ test's capabilities for improved monitoring of melanoma patients at dangerous risk of metastasis and for response to medical treatment. Director Donald Miller M.D., Ph.D. and Deputy Director Jason A. Chesney, M.D., Ph.D., will be co-investigators of the planned study to detect earlier signs of change in disease status. Researchers expect the pT™ will provide a unique insight into cancer status leading to improved medical response options, including therapy. Equally important, this test stands to be an earlier indicator or remission or relapse. In all, the test stands to help answer those age-old questions, "Am I winning my battle with cancer?" and "Is my cancer gone?"
Current medical practice frequently relies on medical imaging procedures, like CT scans, to monitor melanoma patients. But due to the high dose radiation exposure from each procedure, their use by physicians is limited, which can hinder patient monitoring. In addition, the FDA is striving to reduce unnecessary radiation exposure from these medical imaging procedures which are the greatest contributors to total radiation exposure within the U.S.
Alfred "Ben" Jenson, Professor of Vaccinology at the James Graham Brown Cancer Center and co-inventor of the pT™ has been a strong supporter of the pT™'s cancer monitoring potential. Ben is also known for his work as co-inventor of the cervical cancer vaccine, Gardasil, and sees potential for the pT™ as a monitoring tool for a multitude of cancers, including difficult-to-detect oral cancers.
LBIdx™ is a start-up company, focused on the commercialization of pT™ tests for cancer monitoring and prognosis. It is currently raising funds via a crowd funding campaign allowing the public, who will benefit from such a test, to support this enhanced cancer monitoring effort. Crowd funding is a relatively new concept approved by the U.S. Jobs Act of 2012. Details of their 'Breakthrough in Cancer Detection & Monitoring' campaign can be found on the Indiegogo crowd funding website using the following link, http://igg.me/at/CancerDetectionStudy.
About Louisville Bioscience, Inc.
LBIdx™, headquartered in Louisville, Kentucky, is a start-up company with an exclusive license to the University of Louisville Plasma Thermogram™ (pT™) technology and focused on the commercialization of pT™ tests for cancer monitoring and prognosis. The novel pT™ blood test can provide earlier detection of disease, effectively assess status of cancer remission and improve monitoring in response to therapy for numerous cancers including: melanoma, breast, cervical, ovarian and lung cancers. The pT™ diagnostic platform utilizes Differential Scanning Calorimetry (DSC) to generate a robust temperature-induced melting profile of the major blood proteins. The LBIdx™ core technology was invented by the University of Louisville team of Dr. Jonathan Chaires (James Graham Brown Endowed Chair of Cancer Biophysics), Dr. Nichola Garbett and Dr. Alfred "Ben" Jenson. For more information, please visit www.lbidx.com
Media Contact: Michael Birdsell, LBIdx, 502.414.1243, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
Copyright©2012 PR Newswire.
All rights reserved